Literature DB >> 29344211

Prevalence of HPV infection among HIV-positive and HIV-negative women in Central/Eastern Italy: Strategies of prevention.

Edoardo Tartaglia1, Katia Falasca2, Jacopo Vecchiet2, Giovanna Paola Sabusco1, Giovanna Picciano3, Roberto Di Marco1, Claudio Ucciferri1.   

Abstract

The present cross-sectional-study aimed to determine the prevalence of human papillomavirus (HPV)-genotypes among human immunodeficiency virus (HIV)-positive and -negative women in Central/Eastern Italy, and to identify the optimal strategies for effective HPV-prevention in each group. A representative sample of HIV-negative (150/200) and -positive (50/200) women, who underwent cervico-vaginal-swabbing. Swabs were analysed for a cytological screening and for a HPV-DNA-genotyping-test. A total of 66/200 swabs resulted HPV-positive. The overall HPV-prevalence was 33% with a higher prevalence in the HIV-positive-group (48%) compared with the HIV-negative-group (28%). The most frequent genotypes were: 16, 31, 52, 58, 66, 73 and 89. Furthermore, the prevalence of specific genotypes was different in each group. The results of the present study indicate that HIV infection appears to be an independent risk factor for HPV-infection. In addition, HPV-infection is more common and more likely to persist in HIV-positive compared with in HIV-negative women. The optimal way to counteract HPV infection is through primary prevention. The stage of immunity (cluster of differentiation 4-level) at the time of the HPV-screening is one of the most important parameters for detection of susceptibility to HPV-infection and to evaluate the response to the HPV-vaccine in HIV-positive women. It may be used to determine the sub-group of HIV-positive women that are more prone to HPV-infections or that exhibit a partial response to the HPV-vaccine. At present, a novel type of vaccine with 9-genotypes is available and in the near future, it may serve an essential role in the prevention of HPV infections.

Entities:  

Keywords:  HPV-prevalence; HPV-vaccine; human immunodeficiency virus; human papillomavirus; risk factors

Year:  2017        PMID: 29344211      PMCID: PMC5755221          DOI: 10.3892/ol.2017.7140

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  28 in total

1.  Do HPV vaccine genotypes agree with circulating HPV types?

Authors:  Edoardo Tartaglia; Dario Iafusco; Alfonso Galderisi; Pasquale Mastrantonio
Journal:  Lancet Infect Dis       Date:  2011-08       Impact factor: 25.071

2.  Health and Economic Impact of Switching from a 4-Valent to a 9-Valent HPV Vaccination Program in the United States.

Authors:  Marc Brisson; Jean-François Laprise; Harrell W Chesson; Mélanie Drolet; Talía Malagón; Marie-Claude Boily; Lauri E Markowitz
Journal:  J Natl Cancer Inst       Date:  2015-10-04       Impact factor: 13.506

3.  High prevalence of human papillomavirus type 58 in HIV infected men who have sex with men: A preliminary report in Central Italy.

Authors:  Michela Lucia Sammarco; Claudio Ucciferri; Manuela Tamburro; Katia Falasca; Giancarlo Ripabelli; Jacopo Vecchiet
Journal:  J Med Virol       Date:  2015-10-28       Impact factor: 2.327

Review 4.  Effects of tobacco smoking on HIV-infected individuals.

Authors:  Marta Calvo; Montserrat Laguno; María Martínez; Esteban Martínez
Journal:  AIDS Rev       Date:  2015 Jan-Mar       Impact factor: 2.500

5.  Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer.

Authors:  E L Franco; L L Villa; J P Sobrinho; J M Prado; M C Rousseau; M Désy; T E Rohan
Journal:  J Infect Dis       Date:  1999-11       Impact factor: 5.226

6.  Seroprevalence of 9 Human Papillomavirus Types in the United States, 2005-2006.

Authors:  Gui Liu; Lauri E Markowitz; Susan Hariri; Gitika Panicker; Elizabeth R Unger
Journal:  J Infect Dis       Date:  2015-08-27       Impact factor: 5.226

Review 7.  Human papillomavirus vaccination in HIV-infected women: need for increased coverage.

Authors:  Erna Milunka Kojic; Aadia I Rana; Susan Cu-Uvin
Journal:  Expert Rev Vaccines       Date:  2015-11-24       Impact factor: 5.217

Review 8.  The EVER proteins as a natural barrier against papillomaviruses: a new insight into the pathogenesis of human papillomavirus infections.

Authors:  Maciej Lazarczyk; Patricia Cassonnet; Christian Pons; Yves Jacob; Michel Favre
Journal:  Microbiol Mol Biol Rev       Date:  2009-06       Impact factor: 11.056

9.  Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices.

Authors:  Emiko Petrosky; Joseph A Bocchini; Susan Hariri; Harrell Chesson; C Robinette Curtis; Mona Saraiya; Elizabeth R Unger; Lauri E Markowitz
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2015-03-27       Impact factor: 17.586

Review 10.  Association of genital human papillomavirus infection with HIV acquisition: a systematic review and meta-analysis.

Authors:  Pascale Lissouba; Philippe Van de Perre; Bertran Auvert
Journal:  Sex Transm Infect       Date:  2013-08       Impact factor: 3.519

View more
  4 in total

1.  Human immunodeficiency virus is a driven factor of human papilloma virus among women: evidence from a cross-sectional analysis in Yaoundé, Cameroon.

Authors:  Samuel Martin Sosso; Michel Carlos Tommo Tchouaket; Joseph Fokam; Rachel Kamgaing Simo; Judith Torimiro; Aline Tiga; Elise Elong Lobe; Georgia Ambada; Achille Nange; Ezechiel Ngoufack Jagni Semengue; Alex Durand Nka; Valère Tala; Collins Chenwi; Aissatou Abba; Aude Christelle Ka'e; Bouba Yagai; Vittorio Colizzi; Alexis Ndjolo
Journal:  Virol J       Date:  2020-05-19       Impact factor: 4.099

2.  Factors associated with HPV and other self-reported STI coinfections among sexually active Brazilian young adults: cross-sectional nationwide study.

Authors:  Natalia Luiza Kops; Marina Bessel; Jaqueline Driemeyer Correia Horvath; Carla Domingues; Flávia Moreno Alves de Souza; Adele Schwartz Benzaken; Gerson Fernando Mendes Pereira; Ana Goretti Kalume Maranhão; Luisa Lina Villa; Barbara Mello; Eliana Marcia Wendland
Journal:  BMJ Open       Date:  2019-06-21       Impact factor: 2.692

3.  Depiction of Vaginal Microbiota in Women With High-Risk Human Papillomavirus Infection.

Authors:  Zhen-Tong Wei; Hong-Liang Chen; Chun-Feng Wang; Gui-Lian Yang; Shu-Mei Han; Song-Ling Zhang
Journal:  Front Public Health       Date:  2021-01-08

4.  Re-valuation of annual cytology using HPV self-sampling to upgrade prevention (REACH UP): A feasibility study in women living with HIV in the UK.

Authors:  Paola Cicconi; Charlotte Wells; Blanka McCarthy; Susan Wareing; Monique Ingrid Andersson; Julie Fox; Julianne Lwanga; Nisha Pal; Fiona Burns; Clare Woodward; Ramona Malek; Caroline Anne Sabin; Lucy Dorrell
Journal:  HIV Med       Date:  2022-03-03       Impact factor: 3.094

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.